BiologicalDrug
Mogamulizumab clinical trials
Also written KW-0761, Poteligeo and KM8761.
Keep track of what changes. Save the mogamulizumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
Combined with it in one product
Studies by the year they started
33 studies that test it; most in 2023 (4)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2009 | 2 |
| 2010 | 3 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 4 |
| 2024 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 18 · Other 15
Kyowa Kirin Co., Ltd. (9) · Kyowa Kirin, Inc. (6) · National Cancer Institute (NCI) (2) · Memorial Sloan Kettering Cancer Center (2) · Kyowa Kirin China Pharmaceutical Co., Ltd. (1) · Osaka University (1) · City of Hope Medical Center (1) · Stanford University (1)
Often tested with
Tested in the same studies.
Nivolumab (2) · Docetaxel (1) · IDO1 Inhibitor KHK2455 (1) · Recombinant human INTERLEUKIN-15 (1) · Pembrolizumab (1) · Brentuximab Vedotin (1) · Utomilumab (1)
Studies
Open first, then newest update. How each study uses mogamulizumab is read from its arms, and is right about nine times in ten.
Testing it · 33
- Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell LymphomaRecruitingPhase 2City of Hope Medical CenterNCT04930653Written as Mogamulizumab
- Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary SyndromeRecruitingPhase 2Stanford UniversityNCT04256018Written as Mogamulizumab
- Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell LymphomasRecruitingPhase 2University of Michigan Rogel Cancer CenterNCT05956041Written as Mogamulizumab
- Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell LymphomaRecruitingPhase 2Yale UniversityNCT05996185Written as Mogamulizumab
- A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1RecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06698003Written as Mogamulizumab
- Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/LymphomaRecruitingPhase 1John ReneauNCT04848064Written as Mogamulizumab
- Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell LymphomaRecruitingPhase 2European Organisation for Research and Treatment of Cancer - EORTCNCT04128072Written as Mogamulizumab
- A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic TherapyCompletedPhase 4Kyowa Kirin China Pharmaceutical Co., Ltd.NCT06285370Written as Mogamulizumab
- Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis FungoidesSuspendedPhase 1University of Alabama at BirminghamNCT05414500Written as Mogamulizumab
- Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT)SuspendedEarly Phase 1H. Lee Moffitt Cancer Center and Research InstituteNCT06235281Written as Mogamulizumab-Kpkc
- Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung CancerCompletedPhase 1Kyowa Kirin, Inc.NCT02358473Written as mogamulizumab
- Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis FungoidesTerminatedPhase 1/2Emory UniversityNCT04676087Written as Mogamulizumab
- Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)CompletedPhase 2Kyowa Kirin Co., Ltd.NCT01611142Written as KW-0761 (mogamulizumab)
- Mogamulizumab Q4week Dosing in Participants With R/R CTCLActive, not recruitingPhase 2Kyowa Kirin, Inc.NCT04745234Written as Mogamulizumab
- Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell LymphomaCompletedPhase 1/2Kyowa Kirin Co., Ltd.NCT00888927Written as KW-0761
- Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001CompletedPhase 2Kyowa Kirin Co., Ltd.NCT01226472Written as KW-0761
- KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)CompletedPhase 2Kyowa Kirin, Inc.NCT01626664Written as KW-0761
- KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid TumorsCompletedPhase 1Kyowa Kirin, Inc.NCT02867007Written as Mogamulizumab
- Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid TumorsCompletedPhase 1/2Kyowa Kirin, Inc.NCT02705105Written as Mogamulizumab + Nivolumab
- Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCLCompletedPhase 3Kyowa Kirin, Inc.NCT01728805Written as KW-0761
See all 33 studies that test mogamulizumab →
Given in every arm · 2 — mogamulizumab is usual care beside what is tested
- Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to TreatmentTerminatedPhase 1/2National Cancer Institute (NCI)NCT04541017Written as Mogamulizumab
- Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid TumorsCompletedPhase 1Kyowa Kirin, Inc.NCT02301130Written as mogamulizumab
As the comparator · 1 — what is tested is compared with mogamulizumab
Codes
What other systems call mogamulizumab · ClinicalTrials.gg INT005608
- MeSH (NLM) C549035mogamulizumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) YI437801BEMOGAMULIZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 2054068Confirmed FDA, Wikidata
- Wikidata Q6890447mogamulizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C62510MogamulizumabOne source FDA
- DrugBank DB12498One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C549035 | mogamulizumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | YI437801BE | MOGAMULIZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2054068 | — | Confirmed FDA, Wikidata |
| Wikidata | Q6890447 | mogamulizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C62510 | Mogamulizumab | One source FDA |
| DrugBank | DB12498 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.